These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32534795)

  • 1. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
    Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF
    Zhou F; Zhao W; Chen X; Zhang J; Zhou C
    Lung Cancer; 2020 Jan; 139():219-220. PubMed ID: 31640894
    [No Abstract]   [Full Text] [Related]  

  • 3. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.
    Huang Y; Gan J; Guo K; Deng Y; Fang W
    J Thorac Oncol; 2019 Oct; 14(10):e236-e237. PubMed ID: 31558239
    [No Abstract]   [Full Text] [Related]  

  • 7. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
    BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.
    Chimbangu CT; Ya Z; Xi L; Jiayue Z; Xiao M; Ying W; Xingxu Y; Liu X
    Anticancer Drugs; 2024 Jan; 35(1):109-115. PubMed ID: 37578745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
    Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
    Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
    Li S; Lin X; Sun S; Li S; Zhou C
    Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
    Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
    Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
    Tamura A; Inaba Higashiyama R; Yoshida T; Satozono Y; Ohe Y
    Thorac Cancer; 2024 Jun; 15(18):1454-1456. PubMed ID: 38766698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
    Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
    Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
    Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
    Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
    Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
    Dotsu Y; Fukuda M; Honda N; Gyotoku H; Kohno Y; Suyama T; Umeyama Y; Taniguchi H; Takemoto S; Yamaguchi H; Miyazaki T; Sakamoto N; Obase Y; Ikeda H; Ashizawa K; Mukae H
    Thorac Cancer; 2021 Jan; 12(2):272-276. PubMed ID: 33215864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.